These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 23540394)

  • 1. Tobramycin is a suppressor of premature termination codons.
    Altamura N; Castaldo R; Finotti A; Breveglieri G; Salvatori F; Zuccato C; Gambari R; Panin GC; Borgatti M
    J Cyst Fibros; 2013 Dec; 12(6):806-11. PubMed ID: 23540394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.
    Linde L; Boelz S; Nissim-Rafinia M; Oren YS; Wilschanski M; Yaacov Y; Virgilis D; Neu-Yilik G; Kulozik AE; Kerem E; Kerem B
    J Clin Invest; 2007 Mar; 117(3):683-92. PubMed ID: 17290305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergy between Readthrough and Nonsense Mediated Decay Inhibition in a Murine Model of Cystic Fibrosis Nonsense Mutations.
    McHugh DR; Cotton CU; Hodges CA
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonsense-mediated mRNA decay and cystic fibrosis.
    Linde L; Kerem B
    Methods Mol Biol; 2011; 741():137-54. PubMed ID: 21594783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of premature termination codon mutations on CFTR mRNA abundance in human nasal epithelium and intestinal organoids: a basis for read-through therapies in cystic fibrosis.
    Clarke LA; Awatade NT; Felício VM; Silva IA; Calucho M; Pereira L; Azevedo P; Cavaco J; Barreto C; Bertuzzo C; Gartner S; Beekman J; Amaral MD
    Hum Mutat; 2019 Mar; 40(3):326-334. PubMed ID: 30488522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.
    Wilschanski M; Yahav Y; Yaacov Y; Blau H; Bentur L; Rivlin J; Aviram M; Bdolah-Abram T; Bebok Z; Shushi L; Kerem B; Kerem E
    N Engl J Med; 2003 Oct; 349(15):1433-41. PubMed ID: 14534336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene-specific nonsense-mediated mRNA decay targeting for cystic fibrosis therapy.
    Kim YJ; Nomakuchi T; Papaleonidopoulou F; Yang L; Zhang Q; Krainer AR
    Nat Commun; 2022 May; 13(1):2978. PubMed ID: 35624092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene.
    Du M; Jones JR; Lanier J; Keeling KM; Lindsey JR; Tousson A; Bebök Z; Whitsett JA; Dey CR; Colledge WH; Evans MJ; Sorscher EJ; Bedwell DM
    J Mol Med (Berl); 2002 Sep; 80(9):595-604. PubMed ID: 12226741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy.
    Kerem E
    Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion.
    Sharma J; Du M; Wong E; Mutyam V; Li Y; Chen J; Wangen J; Thrasher K; Fu L; Peng N; Tang L; Liu K; Mathew B; Bostwick RJ; Augelli-Szafran CE; Bihler H; Liang F; Mahiou J; Saltz J; Rab A; Hong J; Sorscher EJ; Mendenhall EM; Coppola CJ; Keeling KM; Green R; Mense M; Suto MJ; Rowe SM; Bedwell DM
    Nat Commun; 2021 Jul; 12(1):4358. PubMed ID: 34272367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives.
    Pibiri I; Lentini L; Melfi R; Gallucci G; Pace A; Spinello A; Barone G; Di Leonardo A
    Eur J Med Chem; 2015 Aug; 101():236-44. PubMed ID: 26142488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional Restoration of CFTR Nonsense Mutations in Intestinal Organoids.
    de Poel E; Spelier S; Suen SWF; Kruisselbrink E; Graeber SY; Mall MA; Weersink EJM; van der Eerden MM; Koppelman GH; van der Ent CK; Beekman JM
    J Cyst Fibros; 2022 Mar; 21(2):246-253. PubMed ID: 34666947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introducing sense into nonsense in treatments of human genetic diseases.
    Linde L; Kerem B
    Trends Genet; 2008 Nov; 24(11):552-63. PubMed ID: 18937996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations.
    Mutyam V; Du M; Xue X; Keeling KM; White EL; Bostwick JR; Rasmussen L; Liu B; Mazur M; Hong JS; Falk Libby E; Liang F; Shang H; Mense M; Suto MJ; Bedwell DM; Rowe SM
    Am J Respir Crit Care Med; 2016 Nov; 194(9):1092-1103. PubMed ID: 27104944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids.
    Zomer-van Ommen DD; Vijftigschild LA; Kruisselbrink E; Vonk AM; Dekkers JF; Janssens HM; de Winter-de Groot KM; van der Ent CK; Beekman JM
    J Cyst Fibros; 2016 Mar; 15(2):158-62. PubMed ID: 26255232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.
    Clancy JP; Rowe SM; Bebok Z; Aitken ML; Gibson R; Zeitlin P; Berclaz P; Moss R; Knowles MR; Oster RA; Mayer-Hamblett N; Ramsey B
    Am J Respir Cell Mol Biol; 2007 Jul; 37(1):57-66. PubMed ID: 17347447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonsense-mediated RNA Decay Pathway Inhibition Restores Expression and Function of W1282X CFTR.
    Keenan MM; Huang L; Jordan NJ; Wong E; Cheng Y; Valley HC; Mahiou J; Liang F; Bihler H; Mense M; Guo S; Monia BP
    Am J Respir Cell Mol Biol; 2019 Sep; 61(3):290-300. PubMed ID: 30836009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.
    Sermet-Gaudelus I; Renouil M; Fajac A; Bidou L; Parbaille B; Pierrot S; Davy N; Bismuth E; Reinert P; Lenoir G; Lesure JF; Rousset JP; Edelman A
    BMC Med; 2007 Mar; 5():5. PubMed ID: 17394637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases.
    Keeling KM; Bedwell DM
    Wiley Interdiscip Rev RNA; 2011; 2(6):837-52. PubMed ID: 21976286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.
    Kerem E; Hirawat S; Armoni S; Yaakov Y; Shoseyov D; Cohen M; Nissim-Rafinia M; Blau H; Rivlin J; Aviram M; Elfring GL; Northcutt VJ; Miller LL; Kerem B; Wilschanski M
    Lancet; 2008 Aug; 372(9640):719-27. PubMed ID: 18722008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.